Genmab A/S
Close on Nov 18, 2026
Genmab A/S Employees at Period-End (FTEs): 3,244 in Q3 2026, up 21.0% from a year earlier. That is the highest of the 31 quarters on record here.
Where the Q3 2026 figure comes from
“|| Number of employees (FTE) at the end of the period | 3,244 | 2,681 | 3,244 | 2,681 | 3,029”
Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
Consolidated full-time equivalent employees at period-end across R&D, commercial, and administrative operations (includes ProfoundBio from Q2 2024 and Merus N.V. from Q4 2025).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up employees at Period-End (FTEs)
- R&D Employees at Period-End (FTEs)2,081 · Q3 2026
- SG&A & Commercial Employees at Period-End (FTEs)1,163 · Q3 2026
- United States Employees at Year-End (FTEs)–
- Netherlands Employees at Year-End (FTEs)–
- Denmark Employees at Year-End (FTEs)–
- Japan Employees at Year-End (FTEs)–
- China Employees at Year-End (FTEs)–
Cite this data
StockData. (2026). Genmab A/S Employees at Period-End (FTEs), quarterly Q1 2019–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/fte-end
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?